Crinetics Pharmaceuticals (CRNX) grants CCO 89,000 share awards

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. reported that Chief Commercial Officer Isabel Kalofonos received new equity awards on February 23, 2026. She was granted stock options for 55,000 shares of common stock at an exercise price of $0.00 and 34,000 shares of common stock as restricted stock units.

The restricted stock units represent the right to receive common shares, with 25% vesting annually beginning on March 1, 2027. The stock option vests in forty-eight equal monthly installments starting from February 23, 2026, aligning the CCO’s compensation with long-term company performance through time-based vesting.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kalofonos Isabel

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,000	$0.00	--
Grant/Award	Common Stock	34,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 55,000 shares (Direct); Common Stock — 34,834 shares (Direct)

Footnotes (1)

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalofonos Isabel

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		A		34,000	A	$0(1)	34,834	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.79	02/23/2026		A		55,000		(2)	02/23/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.

2. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did CRNX grant to its Chief Commercial Officer?

Crinetics Pharmaceuticals granted Chief Commercial Officer Isabel Kalofonos 55,000 stock options and 34,000 restricted stock units. These awards provide rights to acquire common stock over time, tying a portion of her compensation to the company’s future share performance and continued service.

How do Isabel Kalofonos’s new stock options at CRNX vest over time?

The 55,000 stock options granted to Isabel Kalofonos vest in forty-eight equal monthly installments. Vesting begins from the commencement date of February 23, 2026, meaning a portion of the options becomes exercisable each month over a four-year period, subject to continued service.

How do the restricted stock units granted to CRNX’s CCO vest?

The 34,000 restricted stock units vest with 25% becoming earned each year. Vesting starts on March 1, 2027, so the award will fully vest in four annual installments, assuming continued service, gradually delivering common shares to the Chief Commercial Officer over that timeframe.

Are the CRNX insider transactions open-market purchases or compensation grants?

The transactions for Isabel Kalofonos are compensation-related grants rather than open-market purchases. They consist of stock options and restricted stock units awarded at a price of $0.00 per share, reflecting equity incentives provided by Crinetics Pharmaceuticals as part of her executive compensation package.

What is the total number of CRNX shares underlying the CCO’s new awards?

Isabel Kalofonos received equity awards tied to 89,000 shares of Crinetics Pharmaceuticals common stock. This total includes 55,000 shares underlying stock options and 34,000 shares represented by restricted stock units, all subject to specified vesting schedules over several years of continued service.